Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tscan Therapeutics Inc (NQ: TCRX ) 6.920 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Tscan Therapeutics Inc < Previous 1 2 3 4 5 Next > TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones March 08, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference March 01, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference February 21, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session January 25, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday January 24, 2023 We're starting the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning! Via InvestorPlace TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors January 23, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress January 05, 2023 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022 December 12, 2022 Poster presents Phase 1 trial design and translational assays to generate early evidence of biological activity in residual leukemia after hematopoietic cell transplantation From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe December 01, 2022 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference November 22, 2022 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting November 11, 2022 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update November 09, 2022 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Virtual Investor Event November 07, 2022 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition November 03, 2022 From TScan Therapeutics, Inc. Via GlobeNewswire TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual Meeting October 05, 2022 From TScan Therapeutics, Inc. Via GlobeNewswire Why HyreCar Is Trading Higher By 60%, Here Are 63 Stocks Moving In Tuesday's Mid-Day Session September 06, 2022 Gainers HyreCar Inc. (NASDAQ: HYRE) jumped 60% to $1.2680 after the company announced it has received a $100 million revolving line of credit from a premier global investment bank and Medalist... Via Benzinga Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday September 06, 2022 Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results. Via Benzinga Why Lululemon Athletica Is Trading Higher By 11%, Here Are 36 Stocks Moving In Friday's Mid-Day Session September 02, 2022 Gainers Via Benzinga 76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More June 23, 2022 Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. Via Benzinga 40 Stocks Moving In Wednesday's Mid-Day Session June 22, 2022 Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. Via Benzinga 71 Biggest Movers From Yesterday May 20, 2022 Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session May 19, 2022 Via Benzinga 110 Biggest Movers From Friday May 16, 2022 Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital. Via Benzinga 56 Stocks Moving In Friday's Mid-Day Session May 13, 2022 Gainers Veru Inc. (NASDAQ: VERU) shares jumped 62.5% to $14.67 after the company reported quarterly results on Thursday. Jefferies maintained Veru with a Buy and raised the price target from $33 to... Via Benzinga 12 Health Care Stocks Moving In Thursday's After-Market Session May 12, 2022 Gainers Via Benzinga Stocks That Hit 52-Week Lows On Thursday May 05, 2022 During Thursday, 351 stocks hit new 52-week lows. Via Benzinga The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute March 09, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc... Via Benzinga Stocks That Hit 52-Week Lows On Wednesday May 04, 2022 During Wednesday's trading, 435 companies set new 52-week lows. Via Benzinga FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic Malignancies January 24, 2022 The FDA has signed off TScan Therapeutics Inc's (NASDAQ: TCRX) investigational new drug (IND) application for TSC-100 in hematologic malignancies patients... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 December 16, 2021 Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE: Via Benzinga < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.